Red blood cells: A neglected compartment in topotecan pharmacokinetic analysis

Anti-Cancer Drugs

Volumn 14, Issue 3, 2003, Pages 227-232

  Loos, Walter J ^a   Gelderblom, Hans ^a,b   Verweij, Jaap ^a   Van Boven Van Zomeren, Desirée M ^a   Nooter, Kees ^a   Stoter, Gerrit ^a   Sparreboom, Alex ^a,c  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Blood distribution; Camptothecin; Gender; Hematocrit

Indexed keywords

CISPLATIN; TOPOTECAN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BINDING AFFINITY; CANCER; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DETERMINATION; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG ERYTHROCYTE LEVEL; DRUG HALF LIFE; DRUG STRUCTURE; ERYTHROCYTE; HUMAN; PHARMACOKINETICS; PRIORITY JOURNAL; SEX DIFFERENCE;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AREA UNDER CURVE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CISPLATIN; ERYTHROCYTES; FEMALE; HALF-LIFE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; NEOPLASMS; PROSPECTIVE STUDIES; SEX FACTORS; TOPOTECAN;

EID: 0037359514     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200303000-00006     Document Type: Article

References (26)

1. Fassberg J, Stella VJ. A kinetic and mechanistic study of the hydrolysis of camptothecin and some analogues. J Pharm Sci 1992; 81:676-684.
2. Hertzberg RP, Caranfa MJ, Holden KG, Jakas DR, Gallagher G, Mattern MR, et al. Modification of the hydroxy lactone ring of camptothecin: inhibition of mammalian topoisomerase I and biological activity. J Med Chem 1989; 32:715-720.
3. Rowinsky EK, Grochow LB, Hendricks CB, Ettinger DS, Forastiere AA, Hurowitz LA, et al. Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor. J Clin Oncol 1992; 10:647-656.
4. Van Warmerdam U, Verweij J, Schellens JHM, Rosing H, Davies BE, de Boer-Dennert M, et al. Pharmacokinetics and pharmacodynamics of topotecan administered daily for 5 days every 3 weeks. Cancer Chemother Pharmacol 1995; 35:237-245.
5. O'Reilly S, Rowinsky EK, Slichenmyer W, Donehower RC, Forastiere AA, Ettinger DS, et al. Phase I and pharmacologic study of topotecan in patients with impaired renal function. J Clin Oncol 1996; 14:3062-3073.
6. Zamboni WC, D'Argenio DZ, Stewart CF, MacVittie T, Farese AM, Tubergen D, et al. Pharmacodynamic model of topotecan-induced time course of neutropenia. Clin Cancer Res 2001; 7:2301-2308.
7. Gerrits CJ, Burris H, Schellens JHM, Planting AS, van der Burg MEL, Rodriguez GI, et al. Five days of oral topotecan (Hycamtin), a phase I and pharmacological study in adult patients with solid tumors. Eur J Cancer 1998; 34:1030-1035.
8. Gerrits CJ, Schellens JHM, Burris H, Eckardt JR, Planting AS, van der Burg MEL, et al. A comparison of clinical pharmacodynamics of different administration schedules of oral topotecan (Hycamtin). Clin Cancer Res 1999; 5:69-75.
9. De Jonge MJA, Loos WJ, Gelderblom H, Planting AST, Van der Burg MEL, Sparreboom A, et al. Phase I pharmacologic study of oral topotecan and intravenous cisplatin: sequence-dependent hematologic side effects. J Clin Oncol 2000; 18:2104-2115.
10. Hinderling PH. Red blood cells: a neglected compartment in pharmacokinetics and pharmacodynamics. Pharmacol Rev 1997; 49:279-295.
11. Synold TW, Newman EM, Carrol M, Muggia FM, Groshen S, Johnson K, et al. Cellular but not plasma pharmacokinetics of lometrexol correlate with the occurrence of cumulative hematological toxicity. Clin Cancer Res 1998; 4:2349-2355.
12. Rosano TG. Effect of hematocrit on cyclosporine (cyclosporin A) in whole blood and plasma of renal-transplant patients. Clin Chem 1985; 31:410-412.
13. Highley MS, Schrijvers D, van Oosterom AT, Harper PG, Momerency G, Van Cauwenberghe K, et al. Activated oxazaphosphoridines are transported predominantly by erythrocytes. Ann Oncol 1997; 8:1139-1144.
14. Momerency G, Cauwenberghe K, Highley MS, Harper PG, van Oosterom AT, de Bruijn EA. Partitioning of ifosfamide and its metabolites between red blood cells and plasma. J Pharm Sci 1996; 85:262-265.
15. Legg B, Rowland M. Saturable binding of cyclosporin A to erythrocytes: estimation of binding parameters in renal transplant patients and implications for bioavailability assessment. Pharm Res 1988; 5:80-85.
16. Peck CO, Barr WH, Benet LZ, Collins J, Desjardins RE, Furst DE, et al. Opportunities for integration of pharmacokinetics, pharmacodynamics, and toxicokinetics in rational drug development. Clin Pharmacol Ther 1992; 51:465-473.
17. Loos WJ, van Zomeren DM, Gelderblom H, Verweij J, Nooter K, Stoker G, et al. Determination of topotecan in human whole blood and unwashed erythrocytes by high-performance liquid chromatography. J Chromatogr B 2002; 766:99-105.
18. Loos WJ, Stoter G, Verweij J, Schellens JHM. Sensitive high-performance liquid chromatographic fluorescence assay for the quantitation of topotecan (SKF 104864-A) and its lactone ring-opened product (hydroxy-acid) in human plasma and urine. J Chromatogr B 1996; 678:309-315.
19. Gout PW, Wijcik LL, Beer CT. Differences between vinblastine and vincristine in distribution in the blood of rats and binding by platelets and malignant cells. Eur J Cancer 1978; 14:1167-1178.
20. Wild MD, Walle UK, Walle T. Extensive and saturable accumulation of paclitaxel by the human platelet. Cancer Chemother Pharmacol 1995; 36:41-44.
21. Gelderblom H, Verweij J, Nooter K, Sparreboom A. Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. Eur J Cancer 2001; 37:1590-1598.
22. Loos WJ, Gelderblom H, Verweij J, Brouwer E, de Jonge MJA, Sparreboom A. Gender-dependent pharmacokinetics of topotecan in adult patients. Anti-Cancer Drugs 2000; 11:673-680.
23. Gallo JM, Laub PB, Rowinsky EK, Grochow LB, Baker SD. Population pharmacokinetic model for topotecan derived from phase I clinical trials. J Clin Oncol 2000; 18:2459-2467.
24. Mi Z, Burke TG. Differential interactions of camptothecin lactone and carboxylate forms with human blood components. Biochemistry 1994; 33:10325-10326.
25. Loos WJ, Verweij J, Gelderblom HJ, De Jonge MJA, Brouwer E, Dallaire BK, et al. Role of erythrocytes and serum proteins in the kinetic profile of total 9-amino-20-(S)-camptothecin in humans. Anti-Cancer Drugs 1999; 10:705-710.
26. Mathijssen RHJ, Loos WJ, Verweij J, de Bruijn P, Sparreboom A. Differential distribution and red blood cell partitioning of irinotecan (CPT-11) and SN-38 in cancer patients. Proc Am Ass Cancer Res 2002; 43:209 (abstr).